| pubmed-article:9326195 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9326195 | lifeskim:mentions | umls-concept:C0012546 | lld:lifeskim |
| pubmed-article:9326195 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:9326195 | lifeskim:mentions | umls-concept:C0023467 | lld:lifeskim |
| pubmed-article:9326195 | lifeskim:mentions | umls-concept:C0312418 | lld:lifeskim |
| pubmed-article:9326195 | lifeskim:mentions | umls-concept:C0162768 | lld:lifeskim |
| pubmed-article:9326195 | lifeskim:mentions | umls-concept:C0036667 | lld:lifeskim |
| pubmed-article:9326195 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:9326195 | pubmed:dateCreated | 1997-12-9 | lld:pubmed |
| pubmed-article:9326195 | pubmed:abstractText | The potential to selectively eliminate acute myeloid leukaemia (AML) cells with the GM-CSF-diphtheria toxin fusion protein (DT-GM-CSF) was studied under conditions of autonomous proliferation in vitro with no growth factors (GFs) added and after growth stimulation with a mixture of human (hu)G-CSF, huIL-3 and huSCF. DNA synthesis was maximally inhibited after 48 h exposure to DT-GM-CSF. Cell viability and AML colony forming ability in vitro were reduced. 18/22 samples were found to be sensitive to DT-GM-CSF, with 50% inhibition of DNA synthesis (ID50) at concentrations ranging from 0.1 to 16 ng/ml, and four samples were minimally or not sensitive to DT-GM-CSF (ID50 > or = 99 ng/ml). From the 15 samples which showed autonomous proliferation, 13 were sensitive to inhibition of proliferation by DT-GM-CSF. The level of GM-CSF receptor (GM-CSFR) expression was determined by flow cytometry after labelling with specific antibodies for the alpha and beta subunits. Although the toxicity to DT-GM-CSF was specifically mediated by the GM-CSFR, no correlation was found between the level of expression of the GM-CSFR alpha or beta subunit and the sensitivity for DT-GM-CSF. These in vitro studies show that the DT-GM-CSF fusion protein can be used for specifically targeting and eliminating leukaemic cells in the majority of AML cases. | lld:pubmed |
| pubmed-article:9326195 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9326195 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9326195 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9326195 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9326195 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9326195 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9326195 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:9326195 | pubmed:issn | 0007-1048 | lld:pubmed |
| pubmed-article:9326195 | pubmed:author | pubmed-author:PastanII | lld:pubmed |
| pubmed-article:9326195 | pubmed:author | pubmed-author:HagenbeekAA | lld:pubmed |
| pubmed-article:9326195 | pubmed:author | pubmed-author:MartensA CAC | lld:pubmed |
| pubmed-article:9326195 | pubmed:author | pubmed-author:KreitmanR JRJ | lld:pubmed |
| pubmed-article:9326195 | pubmed:author | pubmed-author:SERFBB | lld:pubmed |
| pubmed-article:9326195 | pubmed:author | pubmed-author:RozemullerHH | lld:pubmed |
| pubmed-article:9326195 | pubmed:author | pubmed-author:FitzGeraldD... | lld:pubmed |
| pubmed-article:9326195 | pubmed:author | pubmed-author:RomboutsE JEJ | lld:pubmed |
| pubmed-article:9326195 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9326195 | pubmed:volume | 98 | lld:pubmed |
| pubmed-article:9326195 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9326195 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9326195 | pubmed:pagination | 952-9 | lld:pubmed |
| pubmed-article:9326195 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:9326195 | pubmed:meshHeading | pubmed-meshheading:9326195-... | lld:pubmed |
| pubmed-article:9326195 | pubmed:meshHeading | pubmed-meshheading:9326195-... | lld:pubmed |
| pubmed-article:9326195 | pubmed:meshHeading | pubmed-meshheading:9326195-... | lld:pubmed |
| pubmed-article:9326195 | pubmed:meshHeading | pubmed-meshheading:9326195-... | lld:pubmed |
| pubmed-article:9326195 | pubmed:meshHeading | pubmed-meshheading:9326195-... | lld:pubmed |
| pubmed-article:9326195 | pubmed:meshHeading | pubmed-meshheading:9326195-... | lld:pubmed |
| pubmed-article:9326195 | pubmed:meshHeading | pubmed-meshheading:9326195-... | lld:pubmed |
| pubmed-article:9326195 | pubmed:year | 1997 | lld:pubmed |
| pubmed-article:9326195 | pubmed:articleTitle | Sensitivity of human acute myeloid leukaemia to diphtheria toxin-GM-CSF fusion protein. | lld:pubmed |
| pubmed-article:9326195 | pubmed:affiliation | Institute of Haematology, Erasmus University, Rotterdam, The Netherlands. | lld:pubmed |
| pubmed-article:9326195 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9326195 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
